Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
7
×
Tags
boston blog main
boston top stories
7
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
7
×
biotech
new york blog main
new york top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
deals
fda
novartis
alnylam pharmaceuticals
amgen
cancer
gene therapy
medicare
merck
pfizer
roche
spark therapeutics
What
patients
7
×
bio
drug
roundup
fda
gene
help
market
medicine
moves
therapy
acquisitions
advantages
ago
albert
alnylam
analytics
approve
aren’t
awaits
bar
becker
biggest
billions
biofourmis
biological
bourla
brings
cancer
ceo
company
crispr
crossed
data
decades
decision
developers
devices
digital
discovered
Language
unset
unknown
Current search:
photo
×
" boston top stories "
×
" san francisco top stories "
×
patients
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision